Key Drivers
- High asset turnover
- Thin profitability
- Negative working capital
AIAI Summary
Cencora's shift from low‑margin distribution to a specialty‑centric MSO platform (OneOncology + RCM/data/commercialization) reorients the investment thesis toward margin expansion driven by successful integration and specialty commercialization rather than throughput scale. The key actionable call: monitor quarterly free cash flow, deleveraging progress and OneOncology integration milestones—failure to convert specialty volume into predictable operating income or to materially reduce leverage would warrant trimming exposure, while clear signs of sustainable margin capture justify re‑risking the position.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High asset turnover
- •Thin profitability
- •Negative working capital
COR demonstrates massive scale and efficient asset use driving positive EPS and high turnover, but earns only thin margins with strained liquidity, declining cash flow, and premium valuation that outweighs modest returns.
Price Behavior
Key Price Behavior Insights:
- •Below last month SMA
- •Overbought then reversal
- •Immediate $326 support
Trading well below last month's SMA ($355.50) after a sharp reversal from an overbought RSI (~82) into $326.91 signals short-term weakness and a risk of further mean reversion unless price holds $326 and recovers above ~$350.
Sharp drop to $326.91 on 2026-03-20 from overbought conditions
Sentiment & News
Key News Insights:
- •Institutional sell‑off
- •Short‑interest spike
- •CFO succession
Cencora sees heavy institutional selling, rising short interest and a CFO succession amid active investor engagement and a raised outlook.
Expect near‑term share pressure and volatility from repositioning and rising shorts, while guidance and management continuity may temper downside over the medium term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings